



BIOALPHA HOLDINGS BERHAD
(Registration No: 201101021398 (949536-X))
(“BHB” OR THE “COMPANY”)

**INTERIM FINANCIAL REPORT FOR THE
FIRST (1st) QUARTER ENDED 31 MARCH 2026**

Contents	Page
Unaudited Condensed Consolidated Statement of Comprehensive Income	1
Unaudited Condensed Consolidated Statement of Financial Position	3
Unaudited Condensed Consolidated Statement of Changes in Equity	5
Unaudited Condensed Consolidated Statement of Cash Flows	7
Notes to the Unaudited Condensed Consolidated Financial Statements	9

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026

	<--- Individual Quarter ---->		<---- Cumulative Quarter ---->	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Revenue	2,366	2,462	2,366	2,462
Cost of sales	(2,361)	(3,420)	(2,361)	(3,420)
Gross profit/(loss)	5	(958)	5	(958)
Other incomes	1,273	735	1,273	735
Administrative expenses	(3,532)	(2,115)	(3,532)	(2,115)
Net loss on impairment of financial assets	(1,320)	(3,324)	(1,320)	(3,324)
Loss from operations	(3,574)	(5,662)	(3,574)	(5,662)
Finance costs	(93)	(101)	(93)	(101)
Loss before taxation	(3,667)	(5,763)	(3,667)	(5,763)
Taxation	-	150	-	150
Share of profit of associated company	11	12	11	12
Loss for the financial period	(3,656)	(5,601)	(3,656)	(5,601)
Other comprehensive income/(loss) - Exchange differences on translation of foreign operation	638	(1,235)	638	(1,235)
Total comprehensive loss for the period	(3,018)	(6,836)	(3,018)	(6,836)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

	<--- Individual Quarter ---->		<---- Cumulative Quarter ---->	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Loss for the financial period attributable to:				
- Owners of the parent	(3,572)	(5,548)	(3,572)	(5,548)
- Non-controlling interests	(84)	(53)	(84)	(53)
	<u>(3,656)</u>	<u>(5,601)</u>	<u>(3,656)</u>	<u>(5,601)</u>
Total comprehensive loss attributable to:				
- Owners of the parent	(1,529)	(6,808)	(1,529)	(6,808)
- Non-controlling interests	(1,489)	(28)	(1,489)	(28)
	<u>(3,018)</u>	<u>(6,836)</u>	<u>(3,018)</u>	<u>(6,836)</u>
Earnings per share attributable to owners of the parent (sen):				
- Basic	(0.254)	(0.394)	(0.254)	(0.394)
- Diluted	(0.213)	(0.359)	(0.213)	(0.359)

Notes:

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the Audited Financial Statements of BHB for the financial year ended ("FYE") 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2026

	Unaudited As at 31 Mar 2026 RM'000	Audited As at 31 Dec 2025 RM'000
NON-CURRENT ASSETS		
Property, plant and equipment	23,605	24,442
Intangible assets	27,957	28,232
Investment in associates	-	-
	<u>51,562</u>	<u>52,674</u>
CURRENT ASSETS		
Biological assets	170	170
Inventories	3,108	3,485
Trade receivables	1,774	1,556
Other receivables	1,289	1,718
Other investments	12,410	13,729
Tax recoverable	101	105
Fixed deposits with licensed banks	2,155	2,155
Cash and bank balances	2,727	3,554
	<u>23,734</u>	<u>26,472</u>
TOTAL ASSETS	<u>75,296</u>	<u>79,146</u>
EQUITY		
Share capital	76,192	76,192
ICPS	2,889	2,889
Reserves	(11,206)	(9,756)
Equity attributable to owners of the parent	<u>67,875</u>	<u>69,325</u>
Non-controlling interests	(2,502)	(933)
TOTAL EQUITY	<u>65,373</u>	<u>68,392</u>
NON-CURRENT LIABILITIES		
Bank borrowings	460	487
Lease liabilities	2,625	3,299
	<u>3,085</u>	<u>3,786</u>

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2026 (CONT'D)

	Unaudited As at 31 Mar 2026 RM'000	Audited As at 31 Dec 2025 RM'000
CURRENT LIABILITIES		
Contract liabilities	1,947	1,746
Trade payables	475	597
Other payables	3,548	3,828
Bank borrowings	298	311
Lease liabilities	570	486
	6,838	6,968
TOTAL LIABILITIES	9,923	10,754
TOTAL EQUITY AND LIABILITIES	75,296	79,146
NET ASSETS PER SHARE (sen)	4.83 ⁽¹⁾	4.93 ⁽²⁾

Notes:

(1) Based on 1,406,494,277 ordinary shares in BHB as at 31 March 2026.

(2) Based on 1,406,494,277 ordinary shares in BHB as at 31 December 2025.

The unaudited condensed consolidated statement of financial position should be read in conjunction with the Audited Financial Statements of BHB for the FYE 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026

	<----- Attributable to owners of the Company ----->									
	<----- Non-Distributable ----->									
	Share Capital	ICPS	Warrant Reserve	SIS Option Reserve	Merger Deficits	Foreign Currency Translation Reserve	Accumulated losses	Total	Non- Controlling Interests	Total Equity
RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 January 2025	186,191	2,890	18,413	803	(4,569)	4,804	(110,187)	98,345	(629)	97,716
Continuing operations										
Loss for the financial year	-	-	-	-	-	-	(29,625)	(29,625)	(275)	(29,900)
Exchange differences on translation of foreign operation	-	-	-	-	-	(166)	-	(166)	(29)	(195)
Total comprehensive loss	-	-	-	-	-	(166)	(29,625)	(29,791)	(304)	(30,095)
Discontinued operations										
Loss for the financial year	-	-	-	-	-	-	(51)	(51)	-	(51)
Total comprehensive loss	-	-	-	-	-	-	(51)	(51)	-	(51)
Transactions with owners										
Conversion of ICPS	1	(1)	-	-	-	-	-	-	-	-
Shares capital reduction	(110,000)	-	-	-	-	-	110,000	-	-	-
Share-based payment	-	-	-	823	-	-	-	823	-	823
Derecognise SIS	-	-	-	(476)	-	-	476	-	-	-
	(109,999)	(1)	-	347	-	-	110,476	823	-	823
Balance as at 31 December 2025	76,192	2,889	18,413	1,150	(4,569)	4,637	(29,387)	69,325	(933)	68,392

BIOALPHA HOLDINGS BERHAD (Registration No: 201101021398 (949536-X))

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

	----- Attributable to owners of the Company ----->									
	<----- Non-Distributable ----->									
	Share Capital	ICPS	Warrant Reserve	SIS Option Reserve	Merger Deficits	Foreign Currency Translation Reserve	Accumulated losses	Total	Non- Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 January 2026	76,192	2,889	18,413	1,150	(4,569)	4,637	(29,387)	69,325	(933)	68,392
Loss for the financial year	-	-	-	-	-	-	(3,573)	(3,573)	(84)	(3,656)
Exchange differences on translation of foreign operation	-	-	-	-	-	2,122	-	2,122	(1,485)	637
Total comprehensive loss	-	-	-	-	-	2,122	(3,573)	(1,450)	(1,569)	(3,019)
Transactions with owners	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2026	76,192	2,889	18,413	1,150	(4,569)	6,759	(32,960)	67,875	(2,502)	65,373

Note:

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements of BHB for the FYE 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026

	Unaudited Current Period to date 31 Mar 2026 RM'000	Unaudited Preceding Corresponding Period to date 31 Mar 2025 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss before taxation	(3,667)	(5,763)
Adjustments for:		
Amortisation of intangible assets	274	28
Amortisation of deferred capital grant	-	(1)
Amortisation of right-of-use assets	147	72
Depreciation of property, plant and equipment	668	1,408
Gain on disposal of subsidiary	-	(436)
Gain on modification of lease contract	(431)	-
Gain on property, plant and equipment	(35)	-
Fair value gain on biological assets	-	(34)
Fair value loss on quoted shares investments	1,320	3,545
Impairment loss on investment in associates	11	-
Property, plant and equipment written off	-	3
Reversal of allowance for expected credit losses on:		
- Trade receivables	(33)	(188)
- Other receivables	(31)	-
Interest expense	93	101
Interest income	(5)	(28)
Unrealised loss/(gain) on foreign exchange	988	(12)
Operating loss before working capital changes	(701)	(1,305)
Changes in working capital:		
Bill payables	(14)	158
Contract liabilities	317	483
Inventories	377	(229)
Trade receivables	(208)	(433)
Other receivables	439	(598)
Trade payables	(122)	(1,461)
Other payables	(349)	1,018
Cash used in operations	(261)	(2,367)
Interest paid	(3)	(7)
Interest received	5	28
Tax paid	(9)	(15)
Tax refund	14	93
NET CASH USED IN OPERATING ACTIVITIES	(254)	(2,268)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

	Unaudited Current Period to date 31 Mar 2026 RM'000	Unaudited Preceding Corresponding Period to date 31 Mar 2025 RM'000
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(46)	(9)
Proceeds from disposal of property, plant and equipment	35	-
Proceeds from disposal of subsidiary companies	-	180
Net cash outflows arising from disposal of subsidiary	-	(48)
NET CASH (USED IN)/FROM INVESTING ACTIVITIES	(11)	123
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of lease liabilities	(148)	(182)
Repayment of term loans	(27)	(33)
Interest paid	(35)	(42)
NET CASH USED IN FINANCING ACTIVITIES	(210)	(257)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	(475)	(2,402)
EFFECT OF EXCHANGE TRANSLATION DIFFERENCES	(352)	215
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD	3,554	7,207
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD	2,727	5,020
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD COMPRISES:		
Cash and bank balances	2,727	6,020
Fixed deposits with licensed banks	2,155	2,631
	4,882	8,651
Less: Fixed deposits pledged with licensed banks	(955)	(1,431)
Less: Fixed deposits maturity more than 3 months	(1,200)	(2,200)
	2,727	5,020

Note:

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements of BHB for the FYE 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026

A1. Accounting policies and methods of computation

The condensed consolidated interim financial statements are unaudited and have been prepared in accordance with the Malaysian Financial Reporting Standards (“**MFRS**”) 134: Interim Financial Reporting, paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad (“**Bursa Securities**”) (“**Listing Requirements**”).

The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the FYE 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

The financial information presented herein has been prepared in accordance with the accounting policies to be used in preparing the annual consolidated financial statements for the FYE 31 December 2025 under the MFRS framework. These policies do not differ significantly from those used in the audited consolidated financial statements for the FYE 31 December 2025 except as disclosed below:

Standard and amendments to published standards that are effective

On 1 January 2026, the Group applied the following new published standard and amendments to published standards:

- Amendments to MFRS 121, Lack of Exchangeability

The adoption of the above amendments to published standards did not have any significant impact on the current period or any prior period and is not likely to affect future periods.

Standards issued but not yet effective:

The following are accounting standards, amendments and interpretations that have been issued by the Malaysian Accounting Standard Board (“**MASB**”) where the effective has been deferred to a date to be determined by MASB and have not been applied by the Group:

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A1. Accounting policies and methods of computation (Cont'd)

Standards issued but not yet effective (Cont'd):

		Effective dates for financial periods beginning on or after
Amendments to MFRS 1	Annual Improvement to MFRS	1 January 2026
MFRS 7, MFRS 9, MFRS 10 and MFRS 107	Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7	Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 9 and MFRS 7	Contract Referencing Nature- dependent Electricity	1 January 2026
MFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19	Subsidiaries without Public Accountability; Disclosure	1 January 2027
Amendments to MFRS 10 and MFRS 128	Consolidated Financial Statements and Investments in Associates and Joint Ventures - Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be confirmed

A2. Auditors' report of preceding annual financial statements

There was no qualification to the audited consolidated financial statements of the Company for the FYE 31 December 2025.

A3. Seasonal or cyclical factors

The Group's operations are not subject to any significant seasonal or cyclical factors.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A4. Unusual items

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period-to-date.

A5. Material changes in estimates

There were no material changes in estimates of amounts reported in prior interim periods or prior year that would have a material effect on the current quarter's results.

A6. Debt and equity securities

There was no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities for the current financial period-to-date.

A7. Segmental information

The Group's revenue based on the geographical location of its customers is presented as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Malaysia	2,346	2,363	2,346	2,363
Others	20	99	20	99
Total	2,366	2,462	2,366	2,462

The Group has reinforced its core strength by channelling its resources in the manufacturing of health supplement and functional food products, with emphasis on in-demand health categories such as anti-ageing, immunity and other benefits that drives market demand. Efforts taken include communicating with local prospective customers since the cessation of China supply contracts recently, as well as to provide new product development to current existing customers

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A8. Valuation of property, plant and equipment

The Group has not carried out any valuation of its property, plant and equipment in the current quarter.

A9. Capital commitments

	Unaudited Current quarter ended 31 Mar 2026 RM'000	Audited Financial year-to- date 31 Dec 2025 RM'000
Authorised and contracted for:		
Purchase of property, plant and equipment	4,500	4,500

A10. Changes in the composition of the Group

There were no changes in the composition of the Group during the period ended 31 March 2026.

A11. Contingent liabilities

	Unaudited Current quarter ended 31 Mar 2026 RM'000	Audited Financial year-to- date 31 Dec 2025 RM'000
Unsecured:		
Performance bonds in relation to the management of Herbal Integrated Cluster Development	200	200

A12. Material events subsequent to the end of the quarter

There were no other material events subsequent to the end of the current quarter and financial period-to-date that have not been reflected in this interim financial report.

BIOALPHA HOLDINGS BERHAD (Registration No: 201101021398 (949536-X))

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

A13. Related party transactions

There was no additional related party transaction entered into with related parties during the current financial quarter.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B1. Analysis of performance

The Group's current quarter revenue for the financial period ended 31 March 2026 ("**1QFY26**") dropped by 3.9% year-on-year ("**YoY**") to RM2.4 million, as compared to RM2.5 million in the preceding year's corresponding quarter ("**1QFY25**"). The softer performance was primarily due to lower volume order from customers due to soft consumer sentiments.

Further analyses of the performance of the Group's operating segments are as follows:

In 1QFY26, revenue for our manufacturing operations decreased by 3.9% year-on-year ("**YoY**") to RM2.4 million (1QFY25: RM2.5 million). Specifically, domestic manufacturing turnover amounted to RM2.3 million (1QFY25: RM2.4 million), which was attributed to lower volume order from costumers due to soft consumer sentiments.

During the quarter under review, the Group's gross profit amounted to RM5 thousand, compared to a gross loss of RM1.0 million in 1QFY25, as a result of the lower direct cost, ie depreciation and amortisation as compared with 1QFY25. Consequently, net loss attributable to the owners of the parent ("**net loss**") narrowed to RM3.6 million in 1QFY26 (1QFY25: net loss of RM5.5 million).

Comparison with immediate preceding quarter's results

The Group's revenue for the 1QFY26, contributed solely from manufacturing had decreased to RM2.4million, against RM3.2 million in the fourth (4th) quarter ended 31 December 2025. The softer performance was primarily due to lower volume order from customers due to festive season in first quarter.

Net loss for 1QFY26 decreased to RM3.6 million from RM10.0 million in the preceding quarter, primarily due to impairments of financial assets, property, plant and equipment and intangibles assets being recorded in 4Q2025.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B2. Prospects for the financial year ending 31 March 2026

The global economic climate for 2026 remains complex, with heightened geopolitical tensions and lingering economic uncertainties. Nonetheless, the gradual easing of inflationary pressures suggests a potential path towards recovery.

At Bioalpha, we continue to focus on our business strategies, and on optimising costs to navigate external headwinds and seize emerging opportunities.

Bioalpha remains committed to focus on its manufacturing operations, especially on the domestic front, by leveraging resources to expand our offerings with products promising benefit that are in high market demand. At the same time, we are working to secure additional new customers.

Bioalpha is also embarking on the development of an 8-acre agro park in Langkawi, Kedah. This project aims to boost agro-tourism in the region and generate new revenue streams for Bioalpha through the commercialization of high-value herbal products. LADA proposed new allocation of the land, and Board still in consideration.

As we navigate through 2026, the Group shall stay adaptable and resolute in carrying out our strategic initiatives, while maintaining cost efficiency. All in all, we believe that FY2026 performance to be supported by positive contributions from all our segments, barring unforeseen circumstances.

B3. Profit forecast or profit guarantee

The Group has not issued any profit forecast or profit guarantee in any public documents.

B4. Foreign Exchange Exposure / Hedging policy

The Group is exposed to foreign currency risk on transactions that are denominated in currencies other than the respective functional currencies of Group entities. The currencies giving rise to this risk are United States Dollar (“USD”), Chinese Renminbi (“CNY”), Hong Kong Dollar (“HKD”) and Indonesian Rupiah (“IDR”).

The Group have not entered into any derivative instruments for hedging or trading purposes as the net exposure to foreign currency risk is not significant. However, the exposure to foreign currency risk is monitored from time to time by management.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B5. Taxation

	Current quarter ended		Financial period-to-date	
	Unaudited	Unaudited	Unaudited	Unaudited
	31 Mar	31 Mar	31 Mar	31 Mar
	2026	2025	2026	2025
	RM'000	RM'000	RM'000	RM'000

Tax expense recognised in profit or loss:

- Current tax provision	-	(150)	-	(150)
-------------------------	---	-------	---	-------

Effective tax rate (%)	-	-	-	-
------------------------	---	---	---	---

Bioalpha East Coast Agro Sdn Bhd (“**BECASB**”), a wholly-owned subsidiary of the Group, was awarded a tax incentive by the Malaysian Investment Development Authority, which grants BECASB a 100% tax exemption on income for a period of ten (10) years after commercial production date is determined by the relevant authorities.

Bioalpha R&D Sdn Bhd (“**BRDSB**”), a wholly-owned subsidiary of the Group, was awarded BioNexus Status by the Malaysian Bioeconomy Development Corporation Sdn Bhd, which grants BRDSB a 100% tax exemption on income from qualifying activities for a period of ten (10) years ended 30 June 2018 and 20% concessionary tax rate on statutory income for a further ten (10) years, from the financial year ended 2023 to 2032.

Bioalpha (Johor Herbal) Sdn Bhd (“**BJHSB**”), a subsidiary of the Group, was awarded an incentive by Ministry of Agriculture and Agro-Based Industry Malaysia, which allows BJHSB to enjoy 100% tax exemption on income for a period of ten (10) years commencing from 1 January 2018.

Meanwhile, the Group’s other subsidiaries are taxed at the statutory rate of 24% on their chargeable incomes.

B6. Trade receivables

	Unaudited
	31 Mar
	2026
	RM'000
Trade receivables	6,867
Less: Accumulated impairment losses	(5,093)
	<u>1,774</u>

The Group’s normal trade credit terms ranged from 30 to 180 days. Other credit terms are assessed and approved on a case-to-case basis. Trade receivables are recognised at their original invoice amounts which represent their fair value on initial recognition.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B7. Borrowings

The Group's borrowings as at 31 March 2026 are as follows:

	Short term RM'000	Long term RM'000	Total RM'000
Secured			
Bankers' acceptance	189	-	189
Term loans	109	460	569
Total bank borrowings	<u>298</u>	<u>460</u>	<u>758</u>

B8. Material litigation

As at the date of this report, there is no litigation or arbitration, which has a material effect on the financial position of the Group, and the Board is not aware of any other proceedings pending or threatened or of any fact likely to give rise to any other proceedings.

B9. Dividends

The Board did not recommend any dividend during the financial period ended ("FPE") 31 March 2026 (FYE 31 December 2025: Nil).

B10. Earnings per share

The basic earnings per share is calculated as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Net loss attributable to owners of the parent	(3,572)	(5,548)	(3,572)	(5,548)
Weighted average number of ordinary shares in issue ('000)	1,406,494	1,406,491	1,406,494	1,406,491
Basic earnings per share (sen)	<u>(0.254)</u>	<u>(0.394)</u>	<u>(0.254)</u>	<u>(0.394)</u>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B10. Earnings per share (Cont'd)

The diluted earnings per share is calculated as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Net loss attributable to owners of the parent	(3,572)	(5,548)	(3,572)	(5,548)
Weighted average number of ordinary shares in issue ('000)	1,680,193	1,546,900	1,680,193	1,546,900
Diluted earnings per share (sen)	<u>(0.213)</u>	<u>(0.359)</u>	<u>(0.213)</u>	<u>(0.359)</u>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

B11. Disclosure on selected expense/(income) items as required by the Listing Requirements

Included in profit before taxation are the following expense/(income) items:

	Current quarter ended		Financial period-to-date	
	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000	Unaudited 31 Mar 2026 RM'000	Unaudited 31 Mar 2025 RM'000
Depreciation and amortisation expenses	1,089	1,507	1,089	1,507
Fair value (gain)/loss on:				
- Biological assets	-	(34)	-	(34)
- Quoted shares investments	1,320	3,545	1,320	3,545
Gain on modification of term lease	(431)	-	(431)	-
Gain on disposal of property, plant and equipment	(35)	-	(35)	-
Gain on disposal of subsidiary	-	(436)	-	(436)
Loss/(Gain) on unrealised foreign exchange	988	(12)	988	(12)
Impairment loss on investment in associate	11	-	11	-
Property, plant and equipment written off	-	3	-	3
Reversal of allowance for expected credit losses on:				
- Trade receivables	(33)	(188)	(33)	(188)
- other receivables	(31)	-	(31)	-
Interest expenses	93	101	93	101
Interest income	(5)	(28)	(5)	(28)

There was no provision for gain or loss on disposal of properties and exceptional items for the current quarter and financial period-to-date.

BIOALPHA HOLDINGS BERHAD (Registration No: 201101021398 (949536-X))

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST (1st) QUARTER ENDED 31 MARCH 2026 (CONT'D)

C. AUTHORISATION FOR ISSUE

The interim financial report was authorised for issue by the Board in accordance with a resolution of the Board dated 22 May 2026.

By Order of the Board,

WONG YUET CHYN (MAICSA 7047163)

ADELINE TANG KOON LING (LS 0009611)

Company Secretaries

Selangor Darul Ehsan

Dated: 22 May 2026